These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 30008151)

  • 1. Cell adhesion molecules and plasminogen activator inhibitor type-1 (PAI-1) in patients with rheumatoid arthritis: influence of metabolic syndrome.
    de Sá MC; Simão ANC; de Medeiros FA; Iriyoda TMV; Costa NT; Alfieri DF; Flauzino T; Sekiguchi BA; Lozovoy MAB; Reiche EMV; Maes M; Dichi I
    Clin Exp Med; 2018 Nov; 18(4):495-504. PubMed ID: 30008151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell adhesion molecules, plasminogen activator inhibitor type 1, and metabolic syndrome in patients with psoriasis.
    Teixeira GG; Mari NL; de Paula JCC; Cataldi de Alcantara C; Flauzino T; Lozovoy MAB; Martin LMM; Reiche EMV; Maes M; Dichi I; Simão ANC
    Clin Exp Med; 2020 Feb; 20(1):39-48. PubMed ID: 31758356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased adhesion molecule levels in systemic lupus erythematosus: relationships with severity of illness, autoimmunity, metabolic syndrome and cortisol levels.
    da Rosa Franchi Santos LF; Stadtlober NP; Costa Dall'Aqua LG; Scavuzzi BM; Guimarães PM; Flauzino T; Batisti Lozovoy MA; Mayumi Iriyoda TV; Vissoci Reiche EM; Dichi I; Maes M; Colado Simão A
    Lupus; 2018 Mar; 27(3):380-388. PubMed ID: 29400123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis.
    Wållberg-Jonsson S; Cvetkovic JT; Sundqvist KG; Lefvert AK; Rantapää-Dahlqvist S
    J Rheumatol; 2002 May; 29(5):875-82. PubMed ID: 12022343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Sanhuangyilong decoction plus methotrexate on tumor necrosis factor alpha and interferon gamma in serum and synovial fluid in rheumatoid arthritis patients with symptom pattern of damp heat obstruction.
    Liu D; Yan J; Yun M; Yang M; Luo Y; Zhang J; Guo M; Yang M; Yuan W; Zou W; Li H; Hu Y
    J Tradit Chin Med; 2016 Oct; 36(5):625-33. PubMed ID: 29933531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gingival crevicular fluid tissue/blood vessel-type plasminogen activator and plasminogen activator inhibitor-2 levels in patients with rheumatoid arthritis: effects of nonsurgical periodontal therapy.
    Kurgan Ş; Önder C; Balcı N; Fentoğlu Ö; Eser F; Balseven M; Serdar MA; Tatakis DN; Günhan M
    J Periodontal Res; 2017 Jun; 52(3):574-581. PubMed ID: 27781272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis.
    Macías I; García-Pérez S; Ruiz-Tudela M; Medina F; Chozas N; Girón-González JA
    J Rheumatol; 2005 Nov; 32(11):2102-8. PubMed ID: 16265686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review and meta-analysis of circulating adhesion molecules in rheumatoid arthritis.
    Mangoni AA; Zinellu A
    Inflamm Res; 2024 Mar; 73(3):305-327. PubMed ID: 38240792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis.
    Klimiuk PA; Sierakowski S; Latosiewicz R; Cylwik JP; Cylwik B; Skowronski J; Chwiecko J
    Ann Rheum Dis; 2002 Sep; 61(9):804-9. PubMed ID: 12176805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Which factors are related to the presence of atherosclerosis in rheumatoid arthritis?
    Wållberg-Jonsson S; Ohman M; Rantapää-Dahlqvist S
    Scand J Rheumatol; 2004; 33(6):373-9. PubMed ID: 15794194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between serum cell adhesion molecules with hs-CRP, uric acid and VEGF genetic polymorphisms in subjects with metabolic syndrome.
    Ghazizadeh H; Rezaei M; Avan A; Fazilati M; Pasdar A; Tavallaie S; Kazemi E; Seyedi SMR; Ferns GA; Azimi-Nezhad M; Ghayour-Mobarhan M
    Mol Biol Rep; 2020 Feb; 47(2):867-875. PubMed ID: 31873873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Serum tumor necrosis factor alpha (TNF-alpha) concentration correlates with soluble adhesion molecules and vascular endothelial growth factor (VEGF) in rheumatoid arthritis].
    Klimiuk PA; Sierakowski S; Fiedorczyk M; Chwiećko J
    Przegl Lek; 2004; 61(2):86-9. PubMed ID: 15230147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission.
    Toldi G; Bekő G; Kádár G; Mácsai E; Kovács L; Vásárhelyi B; Balog A
    Clin Chem Lab Med; 2013 Feb; 51(2):327-32. PubMed ID: 22718576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the disease activity score using the erythrocyte sedimentation rate and C-reactive protein levels in Koreans with rheumatoid arthritis.
    Son KM; Kim SY; Lee SH; Yang CM; Seo YI; Kim HA
    Int J Rheum Dis; 2016 Dec; 19(12):1278-1283. PubMed ID: 26200604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis.
    Kizaki K; Yamashita F; Hayashi T; Funakoshi N
    Int J Rheum Dis; 2018 Oct; 21(10):1815-1821. PubMed ID: 27778459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of disease activity related cytokines on the fibrinolytic potential and cICAM-1 expression in rheumatoid arthritis.
    Kamper EF; Kopeikina LT; Trontzas P; Potamianou A; Tsiroglou E; Stavridis JC
    J Rheumatol; 2000 Nov; 27(11):2545-50. PubMed ID: 11093432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Niclosamide as an adjuvant to etanercept in treatment patients with active rheumatoid arthritis: an 8-week randomized controlled pilot study.
    Al-Gareeb AIA; Gorial FI; Mahmood AS
    Clin Rheumatol; 2018 Oct; 37(10):2633-2641. PubMed ID: 29882203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rheumatoid Arthritis Patients With Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity.
    Arntz OJ; Pieters BCH; Thurlings RM; Wenink MH; van Lent PLEM; Koenders MI; van den Hoogen FHJ; van der Kraan PM; van de Loo FAJ
    Front Immunol; 2018; 9():2388. PubMed ID: 30420853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can Cytokines be used as an Activation Marker in Rheumatoid Arthritis?
    Kaya FÖ; Ceylan Y; İpek BÖ; Özünal ZG; Sezgin G; Nalbant S
    Endocr Metab Immune Disord Drug Targets; 2021; 21(8):1459-1465. PubMed ID: 33076814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers in Rheumatoid Arthritis, what is new?
    Gavrilă BI; Ciofu C; Stoica V
    J Med Life; 2016; 9(2):144-8. PubMed ID: 27453744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.